Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-HER2 antibody-drug conjugate FDA022-BB05

An antibody-drug conjugate (ADC) composed of trastuzumab, a monoclonal antibody directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2), conjugated, via a valine-alanine (Val-Ala)-based cathepsin B-cleavable linker, to the cytotoxic DNA topoisomerase I inhibitor and exatecan derivative DXd (MAAA-1181a; MAAA-1181), with potential antineoplastic activity. Upon administration, anti-HER2 ADC FDA022-BB05 targets and binds to HER2 expressed on tumor cells. Upon binding, internalization, and linker cleavage, DXd is released. DXd inhibits DNA topoisomerase I activity, thereby inhibiting DNA replication and resulting in cell cycle arrest and tumor cell apoptosis. This inhibits the proliferation of HER2-expressing tumor cells. FDA022-BB05 is also able to induce a bystander effect on neighboring cells in the tumor environment. This further inhibits the proliferation of tumor cells. HER2, a receptor tyrosine kinase that is mutated or overexpressed in many tumor cell types, plays an important role in tumor cell proliferation and tumor vascularization.
Synonym:ADC FDA022-BB05
anti-HER2 ADC FDA022-BB05
trastuzumab/DXd ADC FDA022-BB05
Code name:FDA022 BB05
FDA022-BB05
FDA022BB05
Search NCI's Drug Dictionary